Shima CHEREI, Masoomeh SOFIAN, Alia MOUSAVI, Mohammad BANIFAZL, Ali CHEREI, Arezoo AGHAKHANI, Amitis RAMEZANI

Interlukine-17 and TGF-ß levels in patients with acute brucellosisbefore and after treatment

Background/aim: T-helper cell type 1 (Th1)/Th2 cytokine balance is involved in the resistance or susceptibility to Brucella infection. The analysis of cytokine levels is valuable to determine the role of the immune system in Brucella prognosis. The aim of this study was to investigate the levels of serum interleukin-17 (IL-17) and transforming growth factor beta (TGF-β) and their alterations with treatment in patients with acute brucellosis. Materials and methods: TGF-β was tested in 33 acute brucellosis patients and 19 controls and IL-17 was analyzed in 40 patients and 12 controls. Cytokine levels were tested in controls and patients before and after treatment by ELISA. Results: TGF-β levels were significantly lower in brucellosis cases compared to controls. At the end of the treatment, the serum levels of this cytokine had increased, but there was no significant difference between this cytokine level before and after treatment. The IL-17 level was significantly higher in the brucellosis group compared to controls and its value decreased in patients at the end of treatment without any significant difference. Conclusion: This study indicated that TGF-β was lower and IL-17 was higher in brucellosis cases and, after treatment, the serum level of TGF-β increased and that of IL-17 decreased in these patients.

PDF

___

1. Karaoglan I, Pehlivan S, Namiduru M, Pehlivan M, Kilinçarslan C, Balkan Y, Baydar I. TNF-α, TGF-β, IL10, IL-6 and IFN-γ gene polymorphisms as risk factors for brucellosis. New Microbiol 2009; 32: 173-178.
2. Eskandari-Nasab E, Moghadampour M, Hasani SS, HadadiFishani M, Mirghanizadeh-Bafghi SA, Asadi-Saghandi A, Zare F, Sadeghi-Kalani B, Ghazali-Bina M. Relationship between γ-interferon gene polymorphisms and susceptibility to brucellosis infection. Microbiol Immunol 2013; 57: 785-791.
3. Baldi PC, Giambartolomei GH. Immunopathology of Brucella infection. Recent Pat Antiinfect Drug Discov 2013; 8: 18-26.
4. Pappas G, Memish ZA. Brucellosis in the Middle East: a persistent medical, socioeconomic and political issue. J Chemother 2007; 19: 243-248.
5. Ahmed K, Al-Matrouk KA, Martinez G, Oishi K, Rotimi VO, Nagatake T. Increased serum levels of interferon-gamma and interleukin-12 during human brucellosis. Am J Trop Med Hyg 1999; 61: 425-427.
6. Sofian M, Aghakhani A, Velayati AA, Banifazl M, Eslamifar A, Ramezani A. Risk factors for human brucellosis in Iran: a case control study. Int J Infect Dis 2008; 12: 157-161.
7. Von Bargen K, Gorvel JP, Salcedo SP. Internal affairs: investigating the Brucella intracellular lifestyle. FEMS Microbiol Rev 2012; 36: 533-562.
8. Farahani SH, Shah Mohamadi S, Navidi I, Sofian M. An investigation of the epidemiology of brucellosis in Arak City, Iran, (2001-2010). Arak Med University J 2012; 14: 49-54 (in Persian).
9. Sofian M, Aghakhani A, Banifazl M, Eslamifar A, Zolfaghari F, Sarmadian H, Ramezani A. Differentiation of Brucella-induced epididymo-orchitis from nonspecific epididymo-orchitis in an endemic area for brucellosis. J Med Microbiol Infec Dis 2013, 1: 8-13.
10. Rasouli M, Asaei S, Kalani M, Kiany S, Moravej A. Interleukin17A genetic variants can confer resistance to brucellosis in Iranian population. Cytokine 2013; 61: 297-303.
11. Orozco G, Sánchez E, López-Nevot MA, Caballero A, Bravo MJ, Morata P, de Dios Colmenero J, Alonso A, Martín J. Inducible nitric oxide synthase promoter polymorphism in human brucellosis. Microbes Infect 2003; 5: 1165-1169.
12. Eskandari-Nasab E, Moghadampour M, Asadi-Saghandi A, Kharazi-Nejad E, Rezaeifar A, Pourmasoumi H. Levels of interleukin-(IL)-12p40 are markedly increased in brucellosis among patients with specific IL-12B genotypes. Scand J Immunol 2013; 78: 85-91.
13. Oñate A, Andrews E, Beltran A, Eller G, Schurig G, Folch H. Frequent exposure of mice to crude Brucella abortus proteins down-regulates immune response. J Vet Med B Infect Dis Vet Public Health 2000; 47: 677-682.
14. Dornand J, Gross A, Lafont V, Liautard J, Oliaro J, Liautard JP. The innate immune response against Brucella in humans. Vet Microbiol 2002; 90: 383-394.
15. Fernandes DM, Baldwin CL. Interleukin-10 down regulates protective immunity to Brucella abortus. Infect Immun 1995; 63: 1130-1133.
16. Demirdag K, Ozden M, Kalkan A, Godekmerdan A, Sirri Kilic S. Serum cytokine levels in patients with acute brucellosis and their relation to the traditional inflammatory markers. FEMS Immunol Med Microbiol 2003; 39: 149-153.
17. Bravo MJ, Colmenero JD, Queipo-Ortuño MI, Alonso A, Caballero A. TGF-β1 and IL-6 gene polymorphism in Spanish brucellosis patients. Cytokine 2008; 44: 18-21.
18. Toossi Z, Ellner JJ. The role of TGF beta in the pathogenesis of human tuberculosis. Clin Immunol Immunopathol 1998; 87: 107-114.
19. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6: 1123-1132.
20. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/ T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007; 13: 139-145.
21. Zhan Y, Cheers C. Endogenous gamma interferon mediates resistance to Brucella abortus infection. Infect Immun 1993; 61: 4899-4901.
22. Rodriguez-Zapata M, Salmeron I, Manzano L, Salmeron OJ, Prieto A, Alvarez-Mon M. Defective interferon-gamma production by T-lymphocytes from patients with acute brucellosis. Eur J Clin Invest 1996; 26: 136-140.
23. Galanakis E, Makis A, Bourantas KL, Papadopoulou ZL. Interleukin-3 and interleukin-4 in childhood brucellosis. Infection 2002; 30: 33-34.
24. Refik M, Mehmet N, Durmaz R, Ersoy Y. Cytokine profile and nitric oxide levels in sera from patients with brucellosis. Braz J Med Biol Res 2004; 37: 1659-1663.
25. Kehrl JH. Transforming growth factor-beta: an important mediator of immunoregulation. Int J Cell Cloning 1991; 9: 438- 450.
26. Rafiei A, Hajilooi M, Shakib RJ, Alavi SA. Transforming growth factor-β1 polymorphisms in patients with brucellosis: an association between codon 10 and 25 polymorphisms and brucellosis. Clin Microbiol Infect 2007; 13: 97-100.
27. Budak F, Göral G, Heper Y, Yilmaz E, Aymak F, Baştürk B, Töre O, Ener B, Oral HB. IL-10 and IL-6 gene polymorphisms as potential host susceptibility factors in Brucellosis. Cytokine 2007; 38: 32-36.
28. Akbulut H, Celik I, Akbulut A. Cytokine levels in patients with brucellosis and their relations with the treatment. Indian J Med Microbiol 2007; 25: 387-390.
29. Onishi RM, Gaffen SL. Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129: 311-321.
30. Song X, Qian Y. IL-17 family cytokines mediated signaling in the pathogenesis of inflammatory diseases. Cell Signal 2013; 25: 2335-2347.
31. Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity 2004; 21: 467-476.
32. Clapp B, Skyberg JA, Yang X, Thornburg T, Walters N, Pascual DW. Protective live oral brucellosis vaccines stimulate Th1 and Th17 cell responses. Infect Immun 2011; 79: 4165-4174.